Clearview Wealth Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Clearview Wealth Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-50	Closed	-$17.6K	–	631
2023 Q2	$17.6K	Hold	50	–	–	0.02%	291
2023 Q1	$15.8K	Hold	50	–	–	0.02%	303
2022 Q4	$14.4K	Hold	50	–	–	0.01%	292
2022 Q3	$14K	Hold	50	–	–	0.01%	300
2022 Q2	$14K	Hold	50	–	–	0.01%	321
2022 Q1	$13K	Sell	50 -15	-23%	-$3.56K	0.01%	352
2021 Q4	$14K	Hold	65	–	–	0.01%	373
2021 Q3	$12K	Hold	65	–	–	0.01%	396
2021 Q2	$13K	Sell	65 -138	-68%	-$28.9K	0.01%	388
2021 Q1	$44K	Hold	203	–	–	0.03%	240
2020 Q4	$48K	Buy	+203	New	+$46.6K	0.03%	201

Other funds holding VRTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Clearview Wealth Advisors's VRTX Position: Q3 2023 in Review

Clearview Wealth Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q3 2023, closing a stake of 50 shares — an estimated $17.6K sold.

Clearview Wealth Advisors first reported a position in VRTX in Q4 2020 and held it in 11 quarters. The position peaked at $48K in Q4 2020. 1,277 funds tracked by Wall St. Rank hold VRTX as of Q3 2023.

Clearview Wealth Advisors reported no remaining Vertex Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Clearview Wealth Advisors sold 50 Vertex Pharmaceuticals shares in Q3 2023, an estimated $17.6K.
Clearview Wealth Advisors first reported a position in Vertex Pharmaceuticals in Q4 2020 and held it in 11 quarters.
Clearview Wealth Advisors's Vertex Pharmaceuticals position peaked at $48K in Q4 2020.
1,277 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2023.

Based on Clearview Wealth Advisors's 13F filing for Q3 2023, filed 30 Oct 2023.